MUTYH: Not Just Polyposis

Total Page:16

File Type:pdf, Size:1020Kb

MUTYH: Not Just Polyposis World Journal of W J C O Clinical Oncology Submit a Manuscript: https://www.f6publishing.com World J Clin Oncol 2020 July 24; 11(7): 428-449 DOI: 10.5306/wjco.v11.i7.428 ISSN 2218-4333 (online) REVIEW MUTYH: Not just polyposis Maria Cristina Curia, Teresa Catalano, Gitana Maria Aceto ORCID number: Maria Cristina Curia Maria Cristina Curia, Gitana Maria Aceto, Department of Medical, Oral and Biotechnological 0000-0003-4979-887X; Teresa Sciences, “G. d'Annunzio” University of Chieti-Pescara, Chieti, Via dei Vestini 66100, Italy Catalano 0000-0001-6713-3818; Gitana Maria Aceto 0000-0002-6845- Teresa Catalano, Department of Clinical and Experimental Medicine, University of Messina, 1321. Messina, Via Consolare Valeria 98125, Italy Author contributions: Curia MC, Corresponding author: Maria Cristina Curia, PhD, DSc, Associate Professor, Department of Catalano T and Aceto GM Medical, Oral and Biotechnological Sciences, “G. d'Annunzio” University of Chieti-Pescara, contributed equally to this paper Chieti, Via dei Vestini 66100, Italy. [email protected] with regard to the design of the study, literature review and analysis, writing, and approval of the final version. Abstract MUTYH is a base excision repair enzyme, it plays a crucial role in the correction Supported by the Italian Ministry of DNA errors from guanine oxidation and may be considered a cell protective of University and Research, with factor. In humans it is an adenine DNA glycosylase that removes adenine funds AT-Ricerca2019Curia, misincorporated in 7,8-dihydro-8-oxoguanine (8-oxoG) pairs, inducing G:C to T:A FFABRUNIME2019Catalano and transversions. MUTYH functionally cooperates with OGG1 that eliminates 8- AT-Ricerca2019Aceto. oxodG derived from excessive reactive oxygen species production. MUTYH mutations have been linked to MUTYH associated polyposis syndrome (MAP), an Conflict-of-interest statement: The autosomal recessive disorder characterized by multiple colorectal adenomas. authors declare that they have no MAP patients show a greatly increased lifetime risk for gastrointestinal cancers. conflicts of interest regarding the The cancer risk in mono-allelic carriers associated with one MUTYH mutant allele publication of this paper. is controversial and it remains to be clarified whether the altered functions of this Open-Access: This article is an protein may have a pathophysiological involvement in other diseases besides open-access article that was familial gastrointestinal diseases. This review evaluates the role of MUTYH, selected by an in-house editor and focusing on current studies of human neoplastic and non-neoplastic diseases fully peer-reviewed by external different to colon polyposis and colorectal cancer. This will provide novel insights reviewers. It is distributed in into the understanding of the molecular basis underlying MUTYH-related accordance with the Creative pathogenesis. Furthermore, we describe the association between MUTYH single Commons Attribution nucleotide polymorphisms (SNPs) and different cancer and non-cancer diseases. NonCommercial (CC BY-NC 4.0) We address the utility to increase our knowledge regarding MUTYH in the light license, which permits others to of recent advances in the literature with the aim of a better understanding of the distribute, remix, adapt, build potential for identifying new therapeutic targets. Considering the multiple upon this work non-commercially, functions and interactions of MUTYH protein, its involvement in pathologies and license their derivative works based on oxidative stress damage could be hypothesized. Although the development of extraintestinal cancer in MUTYH heterozygotes is not completely on different terms, provided the defined, the risk for malignancies of the duodenum, ovary, and bladder is also original work is properly cited and increased as well as the onset of benign and malignant endocrine tumors. The the use is non-commercial. See: htt presence of MUTYH pathogenic variants is an independent predictor of poor p://creativecommons.org/licenses prognosis in sporadic gastric cancer and in salivary gland secretory carcinoma, /by-nc/4.0/ WJCO https://www.wjgnet.com 428 July 24, 2020 Volume 11 Issue 7 Curia MC et al. MUTYH in polyposis, cancer and other disorders Manuscript source: Invited while its inhibition has been shown to reduce the survival of pancreatic ductal manuscript adenocarcinoma cells. Furthermore, some MUTYH SNPs have been associated with lung, hepatocellular and cervical cancer risk. An additional role of MUTYH Received: February 28, 2020 seems to contribute to the prevention of numerous other disorders with an Peer-review started: March 2, 2020 inflammatory/degenerative basis, including neurological and ocular diseases. First decision: April 2, 2020 Finally, it is interesting to note that MUTYH could be a new therapeutic target Revised: May 8, 2020 and future studies will shed light on its specific functions in the prevention of Accepted: May 27, 2020 diseases and in the improvement of the chemo-sensitivity of cancer cells. Article in press: May 27, 2020 Published online: July 24, 2020 Key words: MUTYH; Polyposis; Colorectal cancer; Base excision repair; Mutations; Single nucleotide polymorphism P-Reviewer: Ju SQ, Tarnawski AS S-Editor: Zhang H ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. L-Editor: Webster JR E-Editor: Wang LL Core tip: This review focuses on the role of MUTYH, linked to MUTYH associated polyposis syndrome, on human neoplastic and non-neoplastic diseases, different to polyposis and colorectal cancer, considering its involvement in disorders based on oxidative stress damage. MUTYH pathogenic variants are independent predictors of poor prognosis in sporadic gastric, salivary gland secretory, pancreatic ductal, lung and cervical cancers, whereas some variants are involved in degenerative disorders, including neurological and ocular diseases. This provides novel insights for identifying the molecular basis of MUTYH pathogenesis in the light of recent advances, to better understand its potential in disease prevention and identify new therapeutic targets. Citation: Curia MC, Catalano T, Aceto GM. MUTYH: Not just polyposis. World J Clin Oncol 2020; 11(7): 428-449 URL: https://www.wjgnet.com/2218-4333/full/v11/i7/428.htm DOI: https://dx.doi.org/10.5306/wjco.v11.i7.428 INTRODUCTION Biallelic germline MUTYH (MutY homolog Escherichia coli, homolog of MYH, hMYH) gene variants were historically identified in a fraction of Adenomatous Polyposis Coli ( APC) mutation-negative cases with a phenotype overlapping with attenuated familial adenomatous polyposis (AFAP) or classical familial adenomatous polyposis (FAP) (MIM# 604933)[1,2]. In humans, MUTYH protein is considered a cell protective factor able to counteract oxidative damage. It is a DNA glycosylase involved in the restoration of post-replicative mispairs in double-stranded DNA, where MUTYH recognizes and specifically removes adenine or 2-hydroxyadenines misincorporated in 7,8-dihydro-8-oxoguanine (8-oxoG) pairs with adenine or cytosine inducing G:C to T:A transversions as a consequence of DNA replication errors or DNA recombination[3-5]. In 1996 E. coli mutY gene (mutY) was cloned and characterized for the first time[6]. It encodes a protein involved in the bacterial repair system together with mutM, homologous of human 8-Oxoguanine glycosylase 1 (OGG1), and mutT that hydrolyzes 8-oxo-dGTP[7-9]. In E. coli MutY, MutM and MutT compose the GO (formally known as Guanine Oxidation) system responsible for removing and correcting mutations due to adducts[7]. Human MUTYH and OGG1 act like their E. coli homologs MutT and MutM to avoid the mutagenic consequences induced by 8-oxoG. Moreover, MUTYH shows 41% of homology to the E. coli corresponding protein[6]. In 1998, the sequence of SpMYH gene, the mutY homolog of the yeast Schizosaccharomyces pombe, was identified[10]. The SpMYH protein, that removes misincorporated G from 8-oxoG, shows 28% and 31% identity to E. coli MutY and human MUTYH, respectively[10,11]. In 2002, the role of the MUTYH gene in inherited predisposition to colorectal cancer (CRC) was identified in a British family, suggesting that an inefficient MUTYH protein and a defective base excision repair (BER) increase the incidence of somatic G > T transversions in APC gene[1]. Subsequent studies described germline biallelic mutations involved in MUTYH associated polyposis (MAP), a recessive heritable colorectal polyposis with an increased risk of CRC[12,13]. Further research explored MUTYH modifications associated with a hypermutable phenotype involving different organs and the development of various diseases, including cancers, through the WJCO https://www.wjgnet.com 429 July 24, 2020 Volume 11 Issue 7 Curia MC et al. MUTYH in polyposis, cancer and other disorders accumulation of unrepaired 8-oxoG under conditions of oxidative stress. In this review we evaluate biochemical and functional aspects as well as the role of MUTYH in BER. Moreover, we focus on current and updated studies on human diseases induced by alteration of MUTYH through research that associate it with neoplastic and non-neoplastic pathologies different to colon polyposis and CRC. This will produce novel insights into the understanding of the molecular basis underlying MUTYH-related pathogenesis. Furthermore, we describe the association between MUTYH single nucleotide polymorphisms (SNPs) and different cancer and non-cancer diseases. We address the utility to increase our knowledge regarding MUTYH
Recommended publications
  • Relationship Between MUTYH, OGG1 and BRCA1 Mutations and Mrna Expression in Breast and Ovarian Cancer Predisposition
    MOLECULAR AND CLINICAL ONCOLOGY 14: 15, 2021 Relationship between MUTYH, OGG1 and BRCA1 mutations and mRNA expression in breast and ovarian cancer predisposition CARMELO MOSCATELLO1, MARTA DI NICOLA1, SERENA VESCHI2, PATRIZIA DI GREGORIO3, ETTORE CIANCHETTI1, LIBORIO STUPPIA4, PASQUALE BATTISTA1, ALESSANDRO CAMA2, MARIA CRISTINA CURIA1 and GITANA MARIA ACETO1 Departments of 1Medical, Oral and Biotechnological Sciences and 2Pharmacy, ‘G. d'Annunzio’ University of Chieti‑Pescara; 3Department of Psychological, Health and Territorial Sciences, School of Medicine and Health Sciences, ‘G. d'Annunzio’ University of Chieti‑Pescara; 4Immunohaematology and Transfusional Medicine Service, ‘SS. Annunziata’ Hospital, I‑66100 Chieti, Italy Received February 14, 2020; Accepted September 29, 2020 DOI: 10.3892/mco.2020.2177 Abstract. The aetiology of breast and ovarian cancer (BC/OC) family history of cancer, and MUTYH p.Val234Gly in a patient is multi‑factorial. At present, the involvement of base excision with OC, also with a family history of cancer. A significant repair (BER) glycosylases (MUTYH and OGG1) in BC/OC reduced transcript expression in MUTYH was observed predisposition is controversial. The present study investigated (P=0.033) in cases, and in association with the presence of whether germline mutation status and mRNA expression rare variants in the same gene (P=0.030). A significant corre‑ of two BER genes, MUTHY and OGG1, were correlated lation in the expression of the two BER genes was observed with BRCA1 in 59 patients with BC/OC and 50 matched in cases (P=0.004), whereas OGG1 and BRCA1 was signifi‑ population controls. In addition, to evaluate the relationship cantly correlated in cases (P=0.001) compared with controls between MUTYH, OGG1 and BRCA1, their possible mutual (P=0.010).
    [Show full text]
  • Germline TP53 Mutations in Patients with Early-Onset Colorectal Cancer in the Colon Cancer Family Registry
    Research Original Investigation Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry Matthew B. Yurgelun, MD; Serena Masciari, MD; Victoria A. Joshi, PhD; Rowena C. Mercado, MD, MPH; Noralane M. Lindor, MD; Steven Gallinger, MD; John L. Hopper, PhD; Mark A. Jenkins, PhD; Daniel D. Buchanan, PhD; Polly A. Newcomb, PhD, MPH; John D. Potter, MD, PhD; Robert W. Haile, PhD; Raju Kucherlapati, PhD; Sapna Syngal, MD, MPH; for the Colon Cancer Family Registry Supplemental content at IMPORTANCE Li-Fraumeni syndrome, usually characterized by germline TP53 mutations, is jamaoncology.com associated with markedly elevated lifetime risks of multiple cancers, and has been linked to CME Quiz at an increased risk of early-onset colorectal cancer. jamanetworkcme.com and CME Questions page 259 OBJECTIVE To examine the frequency of germline TP53 alterations in patients with early-onset colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS This was a multicenter cross-sectional cohort study of individuals recruited to the Colon Cancer Family Registry (CCFR) from 1998 through 2007 (genetic testing data updated as of January 2015). Both population-based and clinic-based patients in the United States, Canada, Australia, and New Zealand were recruited to the CCFR. Demographic information, clinical history, and family history data were obtained at enrollment. Biospecimens were collected from consenting probands and families, including microsatellite instability and DNA mismatch repair immunohistochemistry results. A total of a 510 individuals diagnosed as having colorectal cancer at age 40 years or younger and lacking a known hereditary cancer syndrome were identified from the CCFR as being potentially eligible.
    [Show full text]
  • XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients
    Int. J. Mol. Sci. 2012, 13, 16658-16667; doi:10.3390/ijms131216658 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article XRCC3 Gene Polymorphism Is Associated with Survival in Japanese Lung Cancer Patients Kayo Osawa 1,*, Chiaki Nakarai 1, Kazuya Uchino 2, Masahiro Yoshimura 2, Noriaki Tsubota 3, Juro Takahashi 1 and Yoshiaki Kido 1,4 1 Faculty of Health Sciences, Kobe University Graduate School of Health Sciences, Kobe 654-0142, Japan; E-Mails: [email protected] (C.N.); [email protected] (J.T.); [email protected] (Y.K.) 2 Department of General Thoracic Surgery, Hyogo Cancer Center, Akashi 673-0021, Japan; E-Mails: [email protected] (K.U.); myoshi@ hp.pref.hyogo.jp (M.Y.) 3 Department of Thoracic Oncology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan; E-Mail: [email protected] 4 Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-78-796-4581; Fax: +81-78-796-4509. Received: 28 September 2012; in revised form: 7 November 2012 / Accepted: 28 November 2012 / Published: 5 December 2012 Abstract: We focused on OGG1 Ser326Cys, MUTYH Gln324His, APEX1 Asp148Glu, XRCC1 Arg399Gln, and XRCC3 Thr241Met and examined the relationship between the different genotypes and survival of Japanese lung cancer patients. A total of 99 Japanese lung cancer patients were recruited into our study. Clinical data were collected, and genotypes of the target genes were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
    [Show full text]
  • Differential Expression Profile Analysis of DNA Damage Repair Genes in CD133+/CD133‑ Colorectal Cancer Cells
    ONCOLOGY LETTERS 14: 2359-2368, 2017 Differential expression profile analysis of DNA damage repair genes in CD133+/CD133‑ colorectal cancer cells YUHONG LU1*, XIN ZHOU2*, QINGLIANG ZENG2, DAISHUN LIU3 and CHANGWU YUE3 1College of Basic Medicine, Zunyi Medical University, Zunyi; 2Deparment of Gastroenterological Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi;3 Zunyi Key Laboratory of Genetic Diagnosis and Targeted Drug Therapy, The First People's Hospital of Zunyi, Zunyi, Guizhou 563003, P.R. China Received July 20, 2015; Accepted January 6, 2017 DOI: 10.3892/ol.2017.6415 Abstract. The present study examined differential expression cells. By contrast, 6 genes were downregulated and none levels of DNA damage repair genes in COLO 205 colorectal were upregulated in the CD133+ cells compared with the cancer cells, with the aim of identifying novel biomarkers for COLO 205 cells. These findings suggest that CD133+ cells the molecular diagnosis and treatment of colorectal cancer. may possess the same DNA repair capacity as COLO 205 COLO 205-derived cell spheres were cultured in serum-free cells. Heterogeneity in the expression profile of DNA damage medium supplemented with cell factors, and CD133+/CD133- repair genes was observed in COLO 205 cells, and COLO cells were subsequently sorted using an indirect CD133 205-derived CD133- cells and CD133+ cells may therefore microbead kit. In vitro differentiation and tumorigenicity assays provide a reference for molecular diagnosis, therapeutic target in BABA/c nude mice were performed to determine whether selection and determination of the treatment and prognosis for the CD133+ cells also possessed stem cell characteristics, in colorectal cancer.
    [Show full text]
  • Regulation of Oxidative DNA Damage Repair by DNA Polymerase Λ and Mutyh by Cross-Talk of Posttranslational Modifications
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2011 Regulation of oxidative DNA damage repair by DNA polymerase lambda and MutYH by cross-talk of posttranslational modifications Markkanen, Enni Emilia Other titles: Regulation of oxidative DNA damage repair by DNA polymerase ฀ and MutYH by cross-talk of posttranslational modifications Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-57042 Dissertation Originally published at: Markkanen, Enni Emilia. Regulation of oxidative DNA damage repair by DNA polymerase lambda and MutYH by cross-talk of posttranslational modifications. 2011, University of Zurich, Faculty of Science. Regulation of Oxidative DNA Damage Repair by DNA Polymerase λ and MutYH by Cross-talk of Posttranslational Modifications Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Enni Emilia Markkanen von Stallikon, ZH Promotionskomitee Prof. Dr. Ulrich Hübscher (Vorsitz) Prof. Dr. Massimo Lopes Prof. Dr. Grigory Dianov (External expert) Zürich, 2012 TO MY FAMILY -­ ÄITI, ISI, TIIA, SHIVA, LITTLE FOOT AND PADDINGTON -­ FOR ALL THEIR LOVE AND ENDLESS SUPPORT. TABLE OF CONTENTS ABBREVIATIONS 4 SUMMARY 5 English 5 German 6 INTRODUCTION 7 General introduction 7 Oxygen as a friend and enemy: the 8-­oxo-­G problem 9 DNA POLYMERASES, THE KEY ENZYMES FOR DNA REPLICATION AND DNA REPAIR
    [Show full text]
  • Silencing of Human DNA Polymerase J Causes Replication Stress and Is
    Published online 30 October 2012 Nucleic Acids Research, 2013, Vol. 41, No. 1 229–241 doi:10.1093/nar/gks1016 Silencing of human DNA polymerase j causes replication stress and is synthetically lethal with an impaired S phase checkpoint Elisa Zucca1, Federica Bertoletti1, Ursula Wimmer2, Elena Ferrari2, Giuliano Mazzini1, Svetlana Khoronenkova3, Nicole Grosse2,4, Barbara van Loon2, Grigory Dianov3, Ulrich Hu¨ bscher2 and Giovanni Maga1,* 1Institute of Molecular Genetics IGM-CNR, via Abbiategrasso 207, I-27100 Pavia, Italy, 2Institute of Veterinary Biochemistry and Molecular Biology IVBMB, University of Zu¨ rich-Irchel, Winterthurertrasse 190, CH-8057 Zu¨ rich, Switzerland, 3Department of Oncology, Gray Institute for Radiation Oncology and Biology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK and 4Division of Radiation Oncology, Vetsuisse-Faculty, University of Zu¨ rich, Winterthurertrasse 260, CH-8057 Zu¨ rich, Switzerland Received August 10, 2012; Revised October 2, 2012; Accepted October 3, 2012 ABSTRACT mammalian genomes undergo 100 000 modifications per day. The major source of DNA damage is reactive Human DNA polymerase (pol) j functions in base oxygen species (ROS), which are constantly produced excision repair and non-homologous end joining. during normal cell metabolism. When ROS react with We have previously shown that DNA pol j is DNA, they produce oxidized bases, some of which are involved in accurate bypass of the two frequent highly mutagenic lesions. The most frequently generated oxidative lesions, 7,8-dihydro-8-oxoguanine and lesions (103–104 per cell/per day) are 7,8-dihydro-8- 1,2-dihydro-2-oxoadenine during the S phase.
    [Show full text]
  • In Vivo Measurements of Interindividual Differences in DNA
    In vivo measurements of interindividual differences in PNAS PLUS DNA glycosylases and APE1 activities Isaac A. Chaima,b, Zachary D. Nagela,b, Jennifer J. Jordana,b, Patrizia Mazzucatoa,b, Le P. Ngoa,b, and Leona D. Samsona,b,c,d,1 aDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; bCenter for Environmental Health Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; cDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and dThe David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139 Edited by Paul Modrich, Howard Hughes Medical Institute and Duke University Medical Center, Durham, NC, and approved October 20, 2017 (received for review July 6, 2017) The integrity of our DNA is challenged with at least 100,000 lesions with increased cancer risk and other diseases (8–10). However, per cell on a daily basis. Failure to repair DNA damage efficiently the lack of high-throughput assays that can reliably measure in- can lead to cancer, immunodeficiency, and neurodegenerative dis- terindividual differences in BER capacity have limited epidemio- ease. Base excision repair (BER) recognizes and repairs minimally logical studies linking BER capacity to disease. Moreover, BER helix-distorting DNA base lesions induced by both endogenous repairs DNA lesions induced by radiation and chemotherapy (3, 11), and exogenous DNA damaging agents. Levels of BER-initiating raising the possibility of personalized treatment strategies using DNA glycosylases can vary between individuals, suggesting that BER capacity in tumor tissue to predict which therapies are most quantitating and understanding interindividual differences in DNA likely to be effective, and using BER capacity in healthy tissue to repair capacity (DRC) may enable us to predict and prevent disease determine the dose individual patients can tolerate.
    [Show full text]
  • Introduction: DNA Signaling by Iron-Sulfur Cluster Proteins
    Chapter 1 Introduction: DNA Signaling by Iron-Sulfur Cluster Proteins Adapted from: Bartels, P.L.; O’Brien, E.; Barton, J.K. DNA Signaling by Iron-Sulfur Cluster Proteins. pp. 405 – 423 in Iron-Sulfur Clusters in Chemistry and Biology, 2nd ed. (ed. Rouault, T.), DeGruyter, Berlin/Boston. [4Fe4S] Clusters in DNA Processing Enzymes and DNA Charge Transport The multi-metal [4Fe4S] clusters in mitochondrial and cytosolic proteins have long been known to serve critical functions ranging from electron transfer to catalysis (1). In an exciting turn, the last three decades have expanded the known cellular distribution of [4Fe4S] clusters to the nucleus, where they occur in DNA-processing enzymes throughout all domains of life (2-12). Table 1.1 illustrates many of these new DNA processing enzymes containing [4Fe4S] clusters. As is evident from the table, [4Fe4S] clusters occur in proteins involved in all aspects of DNA processing. These enzymes are structurally and functionally diverse, acting in a range of pathways from base excision repair (BER) and nucleotide excision repair (NER) to DNA replication. Many of these proteins are known to be disease relevant, and so determining the function of the cluster has been a high priority (13, 14). In all of these proteins, the [4Fe4S] cluster is non-catalytic and largely redox-inert in solution, and only secondarily involved in maintaining structural integrity (15, 16). Despite some evidence to the contrary and the metabolic expense of inserting such a complex cofactor (15 -17), the cluster was typically assigned a structural role. This area remained highly contentious for years, but work in the Barton lab has demonstrated that DNA binding activates these proteins toward redox chemistry through an electrostatically-induced potential shift (18).
    [Show full text]
  • Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer
    G C A T T A C G G C A T genes Review Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer Fabíola Yukiko Miasaki 1 , Cesar Seigi Fuziwara 2, Gisah Amaral de Carvalho 1 and Edna Teruko Kimura 2,* 1 Department of Endocrinology and Metabolism (SEMPR), Hospital de Clínicas, Federal University of Paraná, Curitiba 80030-110, Brazil; [email protected] (F.Y.M.); [email protected] (G.A.d.C.) 2 Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil; [email protected] * Correspondence: [email protected]; Tel.: +55-11-3091-7304 Received: 24 October 2020; Accepted: 16 November 2020; Published: 18 November 2020 Abstract: Thyroid cancer is the most frequent endocrine malignancy with the majority of cases derived from thyroid follicular cells and caused by sporadic mutations. However, when at least two or more first degree relatives present thyroid cancer, it is classified as familial non-medullary thyroid cancer (FNMTC) that may comprise 3–9% of all thyroid cancer. In this context, 5% of FNMTC are related to hereditary syndromes such as Cowden and Werner Syndromes, displaying specific genetic predisposition factors. On the other hand, the other 95% of cases are classified as non-syndromic FNMTC. Over the last 20 years, several candidate genes emerged in different studies of families worldwide. Nevertheless, the identification of a prevalent polymorphism or germinative mutation has not progressed in FNMTC. In this work, an overview of genetic alteration related to syndromic and non-syndromic FNMTC is presented.
    [Show full text]
  • Ligase 1 Is a Predictor of Platinum Resistance and Its Blockade Is Synthetically Lethal In
    Ligase 1 is a predictor of platinum resistance and its blockade is synthetically lethal in XRCC1 deficient epithelial ovarian cancers Reem Ali1*, Muslim Alabdullah1,2*, Mashael Algethami1**, Adel Alblihy1,3**, Islam Miligy2, Ahmed Shoqafi1, Katia A. Mesquita1, Tarek Abdel-Fatah4, Stephen YT Chan4, Pei Wen Chiang5, Nigel P Mongan6,7, Emad A Rakha2, Alan E Tomkinson8, Srinivasan Madhusudan1,3*** 1 Nottingham Biodiscovery Institute, School of Medicine, University of Nottingham, University Park, Nottingham NG7 3RD, UK. 2 Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51PB, UK. 3 Medical Center, King Fahad Security College (KFSC), Riyadh 11461, Saudi Arabia. 4 Department of Oncology, Nottingham University Hospitals, City Hospital Campus, Nottingham NG5 1PB, UK. 5 Department of Obstetrics & Gynaecology, Queens Medical Centre, Nottingham University Hospitals, Nottingham NG7 2UH, UK. 6 Faculty of Medicine and Health Sciences, Centre for Cancer Sciences, University of Nottingham, Sutton Bonington Campus, Sutton Bonington, Leicestershire LE12 5RD, UK 7 Department of Pharmacology, Weill Cornell Medicine, New York, NY, 10065, USA 8 Department of Internal Medicine, Division of Molecular Medicine, Health Sciences Center, The University of New Mexico, Albuquerque, NM 87102, USA. * = Joint first authors, ** = Joint second authors Running title: LIG1 targeting in ovarian cancers Declarations of interest: none Word count: 3459 Figure: 5 Table:1 *** Corresponding author: Professor Srinivasan
    [Show full text]
  • MUTYH, an Adenine DNA Glycosylase, Mediates P53 Tumor Suppression Via PARP-Dependent Cell Death
    OPEN Citation: Oncogenesis (2014) 3, e121; doi:10.1038/oncsis.2014.35 © 2014 Macmillan Publishers Limited All rights reserved 2157-9024/14 www.nature.com/oncsis ORIGINAL ARTICLE MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death SOka1,2, J Leon1, D Tsuchimoto1,2, K Sakumi1,2 and Y Nakabeppu1,2 p53-regulated caspase-independent cell death has been implicated in suppression of tumorigenesis, however, the regulating mechanisms are poorly understood. We previously reported that 8-oxoguanine (8-oxoG) accumulation in nuclear DNA (nDNA) and mitochondrial DNA triggers two distinct caspase-independent cell death through buildup of single-strand DNA breaks by MutY homolog (MUTYH), an adenine DNA glycosylase. One pathway depends on poly-ADP-ribose polymerase (PARP) and the other depends on calpains. Deficiency of MUTYH causes MUTYH-associated familial adenomatous polyposis. MUTYH thereby suppresses tumorigenesis not only by avoiding mutagenesis, but also by inducing cell death. Here, we identified the functional p53-binding site in the human MUTYH gene and demonstrated that MUTYH is transcriptionally regulated by p53, especially in the p53/DNA mismatch repair enzyme, MLH1-proficient colorectal cancer-derived HCT116+Chr3 cells. MUTYH-small interfering RNA, an inhibitor for p53 or PARP suppressed cell death without an additive effect, thus revealing that MUTYH is a potential mediator of p53 tumor suppression, which is known to be upregulated by MLH1. Moreover, we found that the p53-proficient, mismatch repair protein, MLH1-proficient colorectal cancer cell line express substantial levels of MUTYH in nuclei but not in mitochondria, suggesting that 8- oxoG accumulation in nDNA triggers MLH1/PARP-dependent cell death.
    [Show full text]
  • Sirt3 Regulates the Level of Mitochondrial DNA Repair Activity
    ORIGINAL ARTICLE Sirt3 regulates the level of mitochondrial DNA repair activity through deacetylation of NEIL1, NEIL2, OGG1, MUTYH, APE1 and LIG3 in colorectal cancer Authors’ Contribution: A – Study Design 1ABCDEF 1BCDE 2ABE 1 ACDEFG B – Data Collection Jacek Kabziński , Anna Walczak , Michał Mik , Ireneusz Majsterek C – Statistical Analysis 1 D – Data Interpretation Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Lodz, Poland; Head: Prof. Ireneusz Majsterek PhD MD E – Manuscript Preparation 2Department of General and Colorectal Surgery, Medical University of Lodz, Military Medical Academy University Teaching F – Literature Search G – Funds Collection Hospital-Central Veterans’ Hospital, Lodz, Poland; Head: Prof. Adam Dziki PhD MD Article history: Received: 24.03.2019 Accepted: 4.11.2019 Published: 4.11.2019 ABSTRACT: Colorectal cancer (CRC) is one of the most common malignant tumors. One of the factors increasing the risk of its occurrence may be the reduced efficiency of repairing DNA damage, both nuclear and mitochondrial. The main mechanism for repairing oxidative damage is the BER system (in mitochondria mtBER), whose key proteins NEIL1, NEIL2, OGG1, MUTYH, APE1 and LIG3 obtain full efficiency only at the appropriate level of acetylation. Sirtuin 3 is a key protein for mitochondrial homeostasis, regulating a number of metabolic processes related mainly to the control of the level of reactive oxygen species. Because Sirt3 possesses acetylase activity, it can modulate the level of activity of mtBER proteins by their deacetylation. The conducted study showed that the tested proteins NEIL1, NEIL2, OGG1, MUTYH, APE1 and LIG3 are the substrate for the enzymatic deacetylation activity of Sirt3, which may lead to modulation of the risk of CRC, and in cancer cells may be a potential therapeutic target enhancing the action of cytostatic drugs.
    [Show full text]